![](/fileadmin/_processed_/csm_RNF31_Pub_domain__c__RCBS_protein_data_base_62ddf70879.jpg)
Flindr Therapeutics BV secures €20m Series A financing
The Series A financing was led by V-Bio Ventures and an international syndicate that includes Johnson & Johnson Innovation – JJDC, Inc., QBIC...
![](/fileadmin/_processed_/csm_BMS_Evotec_072382e6ec.png)
Evotec SE cashes in €20m milestone
The partnership initiated in 2016 uses Evotec’s iPSC platform to create predictive patient-derived cell-based disease models that mimic the pathology...
![](/fileadmin/_processed_/csm_valneva_lab-web-STA_3217-scaled_e65f26fc69.jpg)
Valneva gets approval for Chikungunya vaccine in Canada
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced today that Health Canada has approved IXCHIQ®, Valneva's single-dose vaccine for the...
![](/fileadmin/_processed_/csm_tubulis_linker_ADC_web_bccd46dac0.jpg)
Tubulis from Munich doses first Patient with own ADC linker technology
Tubulis, based in Martinsried near Munich, announced today that the first patient has been treated in its first Phase 1/2a...
![](/fileadmin/_processed_/csm_Iqvia-obesity_pipeline_0680784a7f.png)
AstraZeneca puts step into obesity market
SixPeaks Bio, launched with US$30m in Series A funding led by Versant Ventures, which is known for its build to buy strategy, and announced a...
![](/fileadmin/_processed_/csm_Ohr_01cd9c4461.jpg)
Sensorion achieves milestones in Phase II trial
Following cochlear implantation, SENS-401, a 5HT3R antagonist that blocks the CalN pathway, reduced sudden hearing loss as measured by the...
![](/fileadmin/_processed_/csm_quantro_747ee92cb9.png)
Quantro Therapeutics cashes in milestone payment from Boehringer Ingelheim
Austrian QUANTRO Therapeutics GmbH has reached a key milestone in its three year R&D and licence option collaboration with Boehringer...